Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07594119 RAP-219 Seizures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07594119 clinical trial report covering RAP-219, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261873 Chaihuang Lidan Capsule Cholecystitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261873 clinical trial report covering Chaihuang Lidan Capsule, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07596589 Remimazolam Tosylate Sedation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07596589 clinical trial report covering Remimazolam Tosylate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07595003 4-Methylumbelliferyl Trimebutine Sulfate Chronic cholecystitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07595003 clinical trial report covering 4-Methylumbelliferyl Trimebutine Sulfate, Phase 3, endpoints, sponsor, geography, readout timing and development wh
Latest Hotspot
8 min read
NCT07597395 Tretinoin Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07597395 clinical trial report covering Tretinoin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07595939 Ruxolitinib Nonsegmental vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07595939 clinical trial report covering Ruxolitinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07595276 Cetuximab biosimilar (Zhangjiang Biotech) Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07595276 clinical trial report covering Cetuximab biosimilar (Zhangjiang Biotech), Phase 3, endpoints, sponsor, geography, readout timing and development w
Latest Hotspot
8 min read
NCT07595549 Berobenatide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07595549 clinical trial report covering Berobenatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07596199 Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed(GlaxoSmi Diphtheria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07596199 clinical trial report covering Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed(GlaxoSmi, Phase 3, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07596173 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbe Diphtheria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07596173 clinical trial report covering Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbe, Phase 3, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07595913 Alveltamig Advanced Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07595913 clinical trial report covering Alveltamig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07596784 Ravulizumab-CWVZ Myasthenia Gravis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07596784 clinical trial report covering Ravulizumab-CWVZ, Phase 3, endpoints, sponsor, geography, readout timing and development white space.